Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation

Orexigen Therapeutics, Inc. (OREXQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/04/2012 PRN Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
07/09/2012 PRN Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
06/06/2012 PRN Orexigen® Therapeutics and Sharecare® Announce Partnership for WeightMate™, a Comprehensive Weight Management Program
05/31/2012 PRN Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
04/27/2012 PRN Lota S. Zoth Joins Orexigen Therapeutics Board of Directors
02/06/2012 PRN Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave® Outcomes Trial
12/22/2011 PRN Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
12/14/2011 PRN Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
10/03/2011 PRN Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
06/01/2011 PRN Orexigen® Therapeutics Schedules June 3, 2011 Webcast and Conference Call to Provide a Regulatory Update on Contrave® NDA
05/02/2011 PRN Orexigen® Therapeutics Schedules May 9, 2011 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2011
04/26/2011 PRN Orexigen® Therapeutics Announces Upcoming Data Presentations at The American College of Obstetricians and Gynecologists Annual Clinical Meeting
04/04/2011 PRN Orexigen?? Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
03/29/2011 PRN Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
03/10/2011 PRN Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
03/10/2011 PRN Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
03/03/2011 PRN Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
02/17/2011 PRN Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
02/09/2011 PRN Orexigen® Therapeutics Announces Corporate Realignment
07/29/2010 PRN Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
06/26/2010 PRN Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
06/25/2010 PRN Orexigen(R) Therapeutics Presents New Data Showing Contrave(R) Significantly Lowers Weight, Improves Blood Glucose Control in Obese Patients With Type 2 Diabetes
06/25/2010 PRN Orexigen(R) Therapeutics Presents New Data Showing Contrave(R) Significantly Lowers Weight, Improves Blood Glucose Control in Obese Patients With Type 2 Diabetes
06/21/2010 PRN Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association Annual Scientific Meeting

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy